Minerva Neurosciences, Inc: valuation

NERVNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.00

November 20, 2026Market cap $100M

What Ploutos Investor adds for Minerva Neurosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $2.00 (November 20, 2026), beside the median of its past fiscal years.

EV / EBIT
–
EV / Revenue
–
Earnings yield
–
FCF yield
–
Market cap
$100M
enterprise value –

DCF calculator

What is Minerva Neurosciences worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
-$31M
Net cash
–
Shares
49.84M
FCF, 5-year average a year
–
Revenue, 5-year average a year
–
Price
$2.00

The full analysis

What do Minerva Neurosciences's filings show?

The multiples say what the market pays for Minerva Neurosciences. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NERV's valuation

Didn't find what you were looking for?

Ask us
How do I work out what NERV is worth?

With the DCF calculator: it opens with Minerva Neurosciences's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.